文献速递银屑病与炎症性皮肤病

银屑病患者使用伊奇珠单抗的炎症性肠病裁定数据分析

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
PubMed 文献 · J Am Acad Dermatol · 2016-12-24

基于7项随机对照和非对照试验的整合数据库,4209例接受伊奇珠单抗治疗的银屑病患者中,裁定明确或可能的炎症性肠病(IBD)19例,克罗恩病发生率1.1/1000患者暴露年,溃疡性结肠炎1.9/1000患者暴露年,总体不常见(<1%)。

要点

  • 伊奇珠单抗治疗银屑病患者中裁定IBD发生率<1%,总体不常见。
  • 克罗恩病发生率1.1/1000患者暴露年,溃疡性结肠炎1.9/1000患者暴露年。
  • 有IBD病史的16例患者中12例至今未出现IBD治疗中出现的不良事件。

核心结论

  • 在7项伊奇珠单抗银屑病试验的整合数据库中,克罗恩病和溃疡性结肠炎病例不常见(<1%)。

研究设计与样本

  • 分析7项随机对照和非对照试验中整合的不良事件数据,覆盖对照诱导期、对照维持期及所有伊奇珠单抗治疗患者。
  • 共4209例患者(6480患者暴露年)接受伊奇珠单抗暴露。
  • 疑似IBD病例由盲法外部专家依据国际公认标准(Registre Epidemiologique des Maladies de l'Appareil Digestif登记)进行裁定。

主要发现

  • 报告疑似克罗恩病不良事件12例、溃疡性结肠炎不良事件17例。
  • 19例被裁定为明确或可能IBD:克罗恩病7例,发生率1.1/1000患者暴露年;溃疡性结肠炎12例,发生率1.9/1000患者暴露年。
  • 3例发生在诱导期(克罗恩病1例,溃疡性结肠炎2例),7例发生在维持期(克罗恩病4例,溃疡性结肠炎3例)。
  • 有IBD病史的16例患者中,12例至今未出现IBD治疗中出现的不良事件或严重不良事件。

临床怎么用

  • 银屑病患者使用伊奇珠单抗时IBD发生率低,但仍需关注消化道症状。
  • 对有IBD病史的患者,使用伊奇珠单抗期间应保持临床监测。

局限性

  • 临床审查(裁定)并非预设分析。
  • 事后收集的不良事件数据可能受事件发生至收集时间长度限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammatory bowel disease (IBD) occurs more frequently in patients with psoriasis. The 2 diseases have significant genetic overlap, but the pathogenesis underlying their co-occurrence is unknown. OBJECTIVE: We sought to report adjudicated IBD cases (Crohn's disease [CD] and ulcerative colitis [UC]) in patients exposed to ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A. METHODS: Adverse events (AEs) integrated from 7 randomized controlled and uncontrolled trials were analyzed for the controlled induction period, controlled maintenance period, and all ixekizumab-treated patients. Suspected IBD cases were reviewed by blinded external experts using internationally recognized criteria (Registre Epidemiologique des Maladies de l'Appareil Digestif registry). RESULTS: In all, 4209 patients (6480 patient-exposure years) were exposed to ixekizumab. Suspected CD (N = 12) or UC (N = 17) AEs were reported; 19 were adjudicated as definite/probable IBD (CD, N = 7, incidence rate = 1.1/1000 patient-exposure years; UC, N = 12, incidence rate = 1.9/1000 patient-exposure years). Among these, 3 occurred during induction (CD, N = 1; UC, N = 2) and 7 during maintenance (CD, N = 4; UC, N = 3). Twelve of 16 patients with reported IBD history have not had an IBD treatment-emergent AE/serious AE to date. LIMITATIONS: Clinical review (adjudication) was not prespecified. AE data collected post-hoc may have been limited by length of time from occurrence. CONCLUSION: From an integrated database of 7 ixekizumab psoriasis trials, CD and UC cases were uncommon (<1%).

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Reich K, Leonardi C, Langley RG, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2016. PMID: 28027825. doi:10.1016/j.jaad.2016.10.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。